Barclays Maintains Equal-Weight on Dow, Lowers Price Target to $60
Barclays analyst Michael Leithead maintains Dow (NYSE:DOW) with a Equal-Weight and lowers the price target from $72 to $60.
Barclays Maintains Overweight on Axalta Coating Sys, Lowers Price Target to $31
Barclays analyst Michael Leithead maintains Axalta Coating Sys (NYSE:AXTA) with a Overweight and lowers the price target from $34 to $31.
Barclays Maintains Equal-Weight on UWM Hldgs, Lowers Price Target to $4
Barclays analyst Mark Devries maintains UWM Hldgs (NYSE:UWMC) with a Equal-Weight and lowers the price target from $5 to $4.
Barclays Maintains Equal-Weight on Rocket Companies, Lowers Price Target to $8
Barclays analyst Mark Devries maintains Rocket Companies (NYSE:RKT) with a Equal-Weight and lowers the price target from $11 to $8.
Barclays Maintains Overweight on PennyMac Financial Servs, Lowers Price Target to $73
Barclays analyst Mark Devries maintains PennyMac Financial Servs (NYSE:PFSI) with a Overweight and lowers the price target from $90 to $73.
B. Riley Securities Downgrades First Foundation to Neutral, Lowers Price Target to $21
B. Riley Securities analyst Steve Moss downgrades First Foundation (NASDAQ:FFWM) from Buy to Neutral and lowers the price target from $31 to $21.
Morgan Stanley Maintains Overweight on Levi Strauss, Lowers Price Target to $19
Morgan Stanley analyst Kimberly Greenberger maintains Levi Strauss (NYSE:LEVI) with a Overweight and lowers the price target from $33 to $19.
Evercore ISI Group Assumes Marriott Intl at Outperform, Announces Price Target of $165
Evercore ISI Group analyst Duane Pfennigwerth assumes Marriott Intl (NASDAQ:MAR) with a Outperform rating and announces Price Target of $165.
Evercore ISI Group Assumes Diamondrock Hospitality at In-Line, Announces Price Target of $10
Evercore ISI Group analyst Duane Pfennigwerth assumes Diamondrock Hospitality (NYSE:DRH) with a In-Line rating and announces Price Target of $10.
BMO Capital Upgrades Fate Therapeutics to Outperform, Announces $47 Price Target
BMO Capital analyst Etzer Darout upgrades Fate Therapeutics (NASDAQ:FATE) from Market Perform to Outperform and announces $47 price target.